Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703274 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| SCHEMBL382079 | 0.97 | KMT2A (0.58) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| SCHEMBL10401247 | 0.95 | KMT2A (0.56) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| SCHEMBL23705658 | 0.92 | KMT2A (0.53) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| Methyl Alcohol SCHEMBL10664077 | 0.91 | KMT2A (0.57) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| SCHEMBL31252540 | 0.87 | AKR1C3 (0.57) | ALDH1A1MAPTKMT2AGAAUSP2 | |
| SCHEMBL6887590 | 0.87 | ALDH1A1 (0.71) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| SCHEMBL2174173 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL29475563 | 0.81 | ALDH1A1 (0.71) | ALDH1A1MAPTL3MBTL1KMT2AALOX15 | |
| SCHEMBL29173466 | 0.81 | AKR1C3 (0.57) | ALDH1A1MAPTKMT2AALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645902-B | Synthesis method of 1- (4-bromophenyl) piperidine | 蚌埠中实化学技术有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-112645902-A | Synthetic method of 1- (4-bromophenyl) piperidine | 蚌埠中实化学技术有限公司 | 2021-04-13 | — | — | CN | claimed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250214987-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| CN-119409624-A | In nilaparib Process for the preparation of intermediates | 泰迩生物医药泰州有限公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4501915-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | Korea University Research and Business Foundation (KR) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974021-A | Preparation method of thiobenzimidazole derivative and novel intermediate for same | 高丽大学校产学协力团 | 2024-11-15 | — | — | CN | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| US-6020328-A | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties | RESEARCH TRIANGLE INSTITUTE (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999062928-A1 | 17β-AMINO AND HYDROXYLAMINO-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES | RESEARCH TRIANGLE INSTITUTE (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0147361-B1 | 11-BETA-ARYL-ESTRADIENES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-02-08 | — | — | EP | disclosed |
| CN-85102147-B | Process for preparing 11 beta-arylestradienes | 施林股份公司 | 1988-08-31 | — | — | CN | disclosed |
| EP-0116974-B1 | 11-BETA-ARYL-ESTRADIENES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-10-29 | — | — | EP | disclosed |
| US-4609651-A | ANTIGESTATION, ANTIMINERALOCORTICOID | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-09-02 | — | — | US | disclosed |
| US-4536401-A | ANTIPROGESTATION AND ANTIMINERALOCORTICORD EFFECTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-08-20 | — | — | US | disclosed |
| EP-0147361-A2 | 11-Beta-aryl-estradienes, their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-07-03 | — | — | EP | disclosed |
| EP-0116974-A1 | 11-Beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214987-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | WEE1, WEE2, HADHB | ALDH1A1 156/4885MAPT 4632/4885L3MBTL1 848/4885 |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | ALDH1A1 525/4885MAPT 3043/4885L3MBTL1 4636/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ALDH1A1 3624/4885MAPT 3092/4885L3MBTL1 1667/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | ALDH1A1 3624/4885MAPT 3092/4885L3MBTL1 1667/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ALDH1A1 3624/4885MAPT 3092/4885L3MBTL1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.